行情

CBAY

CBAY

CymaBay
NASDAQ

实时行情|Nasdaq Last Sale

1.405
-0.005
-0.38%
交易中 14:50 04/02 EDT
开盘
1.410
昨收
1.410
最高
1.520
最低
1.380
成交量
120.44万
成交额
--
52周最高
13.89
52周最低
1.210
市值
9,675.92万
市盈率(TTM)
-0.9163
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CBAY价格均价为2.733,最高价位5.00,最低价为1.500。

EPS

CBAY 新闻

更多
  • Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 1天前
  • Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
  • Zacks · 03/20 15:44
  • We're Keeping An Eye On CymaBay Therapeutics's (NASDAQ:CBAY) Cash Burn Rate
  • Simply Wall St. · 03/20 11:30
  • B. Riley FBR Maintains Neutral on CymaBay Therapeutics, Lowers Price Target to $1.5
  • Benzinga · 03/18 11:00

所属板块

生物技术和医学研究
+1.03%
制药与医学研究
+1.01%

热门股票

代码
价格
涨跌幅

CBAY 简况

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
展开

微牛提供CymaBay Therapeutics Inc(NASDAQ-CBAY)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CBAY股票新闻,以帮助您做出投资决策。